Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir - CONRAD

Drug Profile

Tenofovir - CONRAD

Alternative Names: (R)-PMPA; GS 1278; PMPA

Latest Information Update: 05 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre for the AIDS Programme of Research in South Africa; Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer CONRAD; Gilead Sciences; Hanmi Pharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Adenine nucleotides; Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • No development reported Hepatitis B

Most Recent Events

  • 12 Dec 2019 Johns Hopkins University and CONRAD plan the phase I DREAM-02 trial for HIV infections (Prevention) in USA in January 2020 (Rectal,Spray) (NCT04195776)
  • 03 Dec 2018 CONRAD plans a phase II trial for HIV infections (Prevention) in December 2018 (NCT03762382)
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in South Korea
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top